Tumor rejection by disturbing tumor stroma cell interactions.
about
The complex and central role of interferon-γ in graft-versus-host disease and graft-versus-tumor activityInflammation and cancer, the mastocytoma P815 tumor model revisited: triggering of macrophage activation in vivo with pro-tumorigenic consequencesMyeloid-derived cells are key targets of tumor immunotherapyCyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth.T cell receptor (TCR) gene therapy to treat melanoma: lessons from clinical and preclinical studies.Adoptively transferred immune T cells eradicate established tumors despite cancer-induced immune suppression.T cells contribute to tumor progression by favoring pro-tumoral properties of intra-tumoral myeloid cells in a mouse model for spontaneous melanoma.Head and neck cancer relapse after chemoradiotherapy correlates with CD163+ macrophages in primary tumour and CD11b+ myeloid cells in recurrencesTargeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptakeDendritic cell recovery post-lymphodepletion: a potential mechanism for anti-cancer adoptive T cell therapy and vaccinationTargeting tumor-associated macrophages as a novel strategy against breast cancer.Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell eliminationProgression of cancer from indolent to aggressive despite antigen retention and increased expression of interferon-gamma inducible genesAdoptive transfer of tumor-primed, in vitro-activated, CD4+ T effector cells (TEs) combined with CD8+ TEs provides intratumoral TE proliferation and synergistic antitumor response.IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer.Induced sensitization of tumor stroma leads to eradication of established cancer by T cells.Inhibition of methylcholanthrene-induced carcinogenesis by an interferon gamma receptor-dependent foreign body reaction.Role of T cell receptor affinity in the efficacy and specificity of adoptive T cell therapies.Intravital imaging of CD8+ T cell function in cancer.IDO1 is an Integral Mediator of Inflammatory Neovascularization.Cancer vaccine by fusions of dendritic and cancer cells.Cancer immunotherapy by fusions of dendritic cells and tumor cells.Peptide-mediated targeting of cytokines to tumor vasculature: the NGR-hTNF example.Accelerated tumour metastasis due to interferon-γ receptor-mediated dissociation of perivascular cells from blood vessels.Mannan-modified adenovirus encoding VEGFR-2 as a vaccine to induce anti-tumor immunity.Targeting high-grade B cell lymphoma with CD19-specific T cells.Cyclophosphamide treatment induces rejection of established P815 mastocytoma by enhancing CD4 priming and intratumoral infiltration of P1E/H-2K(d) -specific CD8+ T cells.Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages.High-dose chemotherapy augments the efficacy of recombinant adenovirus vaccines and improves the therapeutic outcome.In vitro generation of cytotoxic and regulatory T cells by fusions of human dendritic cells and hepatocellular carcinoma cellsKilling of non-Hodgkin lymphoma cells by autologous CD19 engineered T cells.Macrophages Reprogrammed In Vitro Towards the M1 Phenotype and Activated with LPS Extend Lifespan of Mice with Ehrlich Ascites CarcinomaM3 Macrophages Stop Division of Tumor Cells In Vitro and Extend Survival of Mice with Ehrlich Ascites CarcinomaVascular targeting of anti-CD40 antibodies and IL-2 into autochthonous tumors enhances immunotherapy in mice.A VEGFR-3 antagonist increases IFN-γ expression on low functioning NK cells in acute myeloid leukemia.Antagonism by Ganoderma lucidum polysaccharides against the suppression by culture supernatants of B16F10 melanoma cells on macrophage.The Dark Side of IFN-γ: Its Role in Promoting Cancer Immunoevasion.Transfer of Allogeneic CD4+ T Cells Rescues CD8+ T Cells in Anti-PD-L1-Resistant Tumors Leading to Tumor Eradication.Visualizing the dynamic of adoptively transferred T cells during the rejection of large established tumors.Critical role of the Th1/Tc1 circuit for the generation of tumor-specific CTL during tumor eradication in vivo by Th1-cell therapy.
P2860
Q26851545-87CC5F6B-1786-473D-A24C-80B9CDA03511Q28193430-CC2172A7-EE37-4E7B-83B0-899186B9F6F5Q28388246-0CE03510-3327-4353-8EA5-7ED557169C87Q33502208-6E745D39-BC2C-434A-B677-D85A7A74DA02Q33530527-90FCA142-17E6-4E90-AEB3-F5233B2A1B7DQ33854515-439B85AC-6315-4C5B-AD7C-BCFFE03D3FEDQ33919802-182CCAE8-470D-4CC0-9577-6C4F1CCC2777Q34354547-B6A0D83C-B77A-4A5E-BF61-9B2FC630B729Q34691527-C06762FC-A458-44A5-A71E-6BCAC00080C9Q34759603-9637ACAF-FEE6-4EEC-AF65-067B2AD37906Q34803221-53F7552D-54F2-4511-B2C1-C4CAC5F6FAF7Q35012887-310AC76C-8F9C-4551-8AC4-459CF7F3DC20Q35079913-9A5A45A1-5A27-4867-A065-DD653B46A1CCQ35828752-6FB67DA0-BADE-45F2-AD38-DF0A7DA17CC4Q35886767-FDB722A5-A1E7-4552-86D0-5B4A3404AA0AQ36228950-8F95C11B-2548-4F69-82CA-5492393A322CQ36369691-52FF3A49-6F00-4DE4-939D-8EAC2BB028BDQ37107843-D0025447-60B4-49D8-8E59-2CB466B50E4CQ37229840-2DF7D447-BCB8-4CD2-BB98-564214C66F51Q37510171-F57C08E0-97DD-4193-B377-19C917B6AFD4Q37698219-189EC8B3-C496-4564-9BB7-149097ABE1E0Q37773276-B029CBAA-D81E-4171-9686-3E71BD203DEBQ38112578-AD767423-533C-4846-8829-A297F3794A9BQ38707139-DCDF4FE4-FC6B-4680-B98C-5E9625CADED9Q39024097-DF2BD9D1-1A18-4FED-A39A-C35CA41CC7DCQ39026731-103C403F-DCB4-4629-A6A9-569A3C80712CQ39061560-4E9581D6-F5BE-4889-92FE-D213711F5DDAQ39637537-3E653C8D-FC39-4E65-9FFC-AC1ED9BA7993Q39920459-4FD75C26-E85F-42E4-8C87-EFC0758E50A5Q39939752-0BF36215-8665-4545-B5EF-A718B162C688Q40432901-EE769720-AA11-4986-A28E-9B0FC36BCB56Q41213052-24538003-743E-4AB8-B893-CE25B55ED43FQ42324194-B739A68F-7014-467A-8BDB-840A0D7A6E30Q43108657-24DA2BCF-2C5D-497D-8104-1B9BCD2E41DFQ45077403-7BC08AC8-9FD9-4866-9C7C-34BE188CC4BAQ45326678-2AC6BA4B-F963-460F-BEB4-5494F1A3B72FQ48337458-FE7F6FC0-801F-47C6-A1A3-30E0CEE1CEAFQ50957786-5487BE4F-96BB-4D4D-AA5F-1DBEB1010CC9Q50993575-26015FC9-70E0-4FCD-87B3-68BABA01EF48Q52005100-7B6DB36E-B98A-4D37-9E22-B0B40EA819CF
P2860
Tumor rejection by disturbing tumor stroma cell interactions.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
Tumor rejection by disturbing tumor stroma cell interactions.
@en
Tumor rejection by disturbing tumor stroma cell interactions.
@nl
type
label
Tumor rejection by disturbing tumor stroma cell interactions.
@en
Tumor rejection by disturbing tumor stroma cell interactions.
@nl
prefLabel
Tumor rejection by disturbing tumor stroma cell interactions.
@en
Tumor rejection by disturbing tumor stroma cell interactions.
@nl
P2093
P2860
P356
P1476
Tumor rejection by disturbing tumor stroma cell interactions.
@en
P2093
P2860
P304
P356
10.1084/JEM.194.11.1549
P407
P577
2001-12-01T00:00:00Z